Viridian Therapeutics, Inc.\DE (VRDN) FY2025 10-K Annual Report
Viridian Therapeutics, Inc.\DE (VRDN) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Viridian Therapeutics, Inc.\DE FY2025 10-K Analysis
Business Overview
- • Core biopharma focus on autoimmune and rare diseases, emphasizing best-in-class therapies for thyroid eye disease (TED) and related conditions
- • New subcutaneous IGF-1R antibody elegrobart in pivotal phase 3 (REVEAL-1/2) for TED with potential auto-injector, complementing intravenous veligrotug
Management Discussion & Analysis
- • Revenue $70.8M in 2025 vs $0.3M in 2024; increase driven by $70M upfront license payment from Kissei and related party collaborations
- • Research & Development expenses $338.9M in 2025 vs $238.3M in 2024; TED portfolio R&D up $78.3M, driven by phase 3 trials and milestone fees
Risk Factors
- • Regulatory risk: FDA may require additional patients or steps for veligrotug and elegrobart phase 3 trials, risking approval delays or denials
- • Geopolitical exposure: Clinical trial operations in Israel and China vulnerable to adverse regulatory actions or unrest impacting progress
Viridian Therapeutics, Inc.\DE FY2025 Key Financial MetricsXBRL
Revenue
$71M
▲ +23359.9% YoY
Net Income
-$343M
▼ -26.9% YoY
Operating Margin
-512.9%
▲ +9850530bp YoY
Net Margin
-483.6%
▲ +8890352bp YoY
ROE
-47.4%
▼ -725bp YoY
Total Assets
$899M
▲ +21.1% YoY
Operating Cash Flow
-$276M
▼ -19.0% YoY
Source: XBRL data from Viridian Therapeutics, Inc.\DE FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Viridian Therapeutics, Inc.\DE
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.